AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ROCKET PHARMACEUTICALS, INC. Director's Dealing 2023

Jun 27, 2023

33148_dirs_2023-06-26_5dc41fc9-b545-4923-8a61-ffa2075ff9b3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2023-06-22

Reporting Person: GRANADILLO PEDRO P (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-22	Stock Option (Right to Buy)	$21.56	A	25850	Acquired	2033-06-22	Common Stock (25850)	Direct
2023-06-22	Stock Option (Right to Buy)	$21.56	A	5026	Acquired	2033-06-22	Common Stock (5026)	Direct

Footnotes

F1: This option represents a right to purchase a total of 25,850 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024.

F2: This option represents a right to purchase a total of 5,026 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 22, 2024. This option was issued to the Reporting Person in lieu of director retainer fees of $70,000.